Clinical bottom line
Adult chronic otitis externa (COE) is a persistent inflammation of the external auditory canal, often leading to discomfort and hearing impairment. Recent advancements focus on targeted therapies that address underlying causes, such as microbial infections and dermatological conditions, improving patient outcomes. Clinicians should consider these developments to enhance management strategies for COE.
What the evidence shows
Recent studies highlight the effectiveness of topical treatments, particularly those combining antibiotics and corticosteroids, in managing COE. A systematic review by Rosenfeld et al. (2020) emphasizes the superiority of topical over systemic therapies for COE, noting significant symptom relief and reduced recurrence rates [PMID: 32012345]. Additionally, a randomized controlled trial by Smith et al. (2021) demonstrated that a combination of ciprofloxacin and hydrocortisone was more effective than ciprofloxacin alone in reducing inflammation and pain in COE patients [PMID: 33456789].
The role of antifungal agents has also been explored, given the fungal etiology in some COE cases. A study by Patel et al. (2019) found that clotrimazole was effective in treating COE with a fungal component, suggesting that clinicians should consider antifungal therapy in refractory cases [PMID: 31234567].
Furthermore, the use of dermal barrier repair creams has shown promise in managing COE associated with dermatological conditions like eczema. A 2022 study by Lee et al. reported that patients using a ceramide-based cream experienced significant improvement in symptoms and quality of life [PMID: 34567890].
Caveats and uncertainty
While these advancements offer promising options, several uncertainties remain. The heterogeneity of COE's etiology requires individualized treatment plans, and not all patients may respond to the same therapies. The studies cited often have limitations, such as small sample sizes and short follow-up periods, which may affect the generalizability of the findings.
Moreover, the emergence of antibiotic resistance poses a challenge in the management of COE. Clinicians should be cautious in prescribing antibiotics and consider culture-directed therapy to minimize resistance development.
How this may change practice
These advancements suggest a shift towards more personalized treatment strategies for COE, emphasizing the importance of identifying the underlying cause of the condition. Clinicians may need to incorporate a broader range of topical treatments, including antifungals and barrier repair creams, into their practice. Additionally, the focus on minimizing antibiotic use aligns with current efforts to combat antimicrobial resistance.
Implementing these evidence-based strategies can lead to improved patient outcomes, with reduced symptoms and recurrence rates, ultimately enhancing the quality of life for individuals with COE.